But, perhaps surprisingly, only one of these differences, that in physical activity, proved to have a significant relationship with lymphocyte production.
Its role in lymphocyte signaling was characterized and explored through lots of cell-based and in vivo models, including RNAi and other target validation approaches.
Pfizer's drug tremelimumab and Bristol-Myers Squibb's ipilimumab are antibodies to a protein called CTLA-4 (cytotoxic T-lymphocyte antigen-4) that acts as an emergency brake to prevent killer T cells from attacking healthy tissue.
Benlysta is delivered directly into a vein (intravenous infusion) and is the first inhibitor designed to target B-lymphocyte stimulator (BLyS) protein, which may reduce the number of abnormal B cells thought to be a problem in lupus.